Xilio reports 48.2M Series B warrants exercised for $35.8M, cash runway into Q2 2027

Xilio Therapeutics, Inc.

48.2M Series B warrants exercised by Dec 31, 2025, yielding $35.8M gross proceeds; issued 8.2M shares and 40M prefunded warrants.
As of Jan 2, 2026, 67.5M shares of common stock outstanding.
48.2M Series C warrants outstanding at $0.75 strike; if fully exercised could add $36.2M gross.
Existing cash plus net proceeds from Series B exercise expected to fund operations into Q2 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.